Evidence map›Paper›PMID 42180189›Full record

ArticleBiochemistry and biophysics reports2026

Tanshinone IIA attenuates psoriasis via Nrf2/HO-1 activation: Mechanistic insights from preclinical models.

Xia Xu, Jingyao Liang, Maofang Huang, Quan Chen, Shijian Xiang, Xianhua Tang, Zhang Jingyue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xia XuDepartment of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong, China.
Jingyao LiangDepartment of Clinical Laboratory, Guangzhou Dermatology Hospital, Guangzhou, Guangdong, China.
Maofang HuangDepartment of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong, China.
Quan ChenDepartment of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong, China.
Shijian XiangDepartment of Pharmacy, The Seventh Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Xianhua TangDepartment of Dermatology, Panyu Maternal and Child Care Service Centre of Guangzhou, Guangzhou, Guangdong, China.
Zhang JingyueDepartment of Clinical Laboratory, Eighth Affiliated Hospital of Guangxi Medical University, Guigang City People's Hospital, Guigang, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Psoriasis is a chronic inflammatory skin disorder driven by oxidative stress and immune dysregulation. Tanshinone IIA, a bioactive compound from Methods: Using H Results: Tanshinone IIA significantly suppressed TNF-α-induced HaCaT proliferation and ROS accumulation. Mechanistically, it promoted Nrf2 nuclear translocation and upregulated HO-1, SOD2, and NQO1 expression. In IMQ-treated mice, it reduced epidermal thickness, scaling, and inflammatory cytokines while enhancing antioxidant defences. Conclusion: Tanshinone IIA mitigates psoriasis via Nrf2/HO-1 activation and thus has therapeutic potential.

Indexed as

Antioxidant therapyNrf2 signallingOxidative stressPsoriasisTanshinone IIA

Identifiers

PMID42180189
PMCPMC13191627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.